Table 6 Drug survival by biologic drug
Biologic drug | Interval | % biologics’ survival (95 % CI) |
|---|---|---|
Etanercept | 3 years | 59 (41–73) |
Infliximab | 3 years | 20 (2–52) |
Adalimumab | 3 years | 54 (33–70) |
Rituximab | 3 years | 45 (10–75) |
Abatacept | 3 years | 63 (33–83) |
Tocilizumab | 2 years | 75 (13–96) |